Price (delayed)
$193.58
Market cap
$341.93B
P/E Ratio
64.53
Dividend/share
$6.13
EPS
$3
Enterprise value
$399.43B
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate
Highlights
The debt rose by 16% year-on-year but it has declined by 4.5% since the previous quarter
ABBV's P/E is 108% above its 5-year quarterly average of 31.0 and 24% above its last 4 quarters average of 52.2
AbbVie's equity has decreased by 47% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of ABBV
Market
Valuations
Earnings
Shares outstanding
1.77B
Market cap
$341.93B
Enterprise value
$399.43B
Price to earnings (P/E)
64.53
Price to book (P/B)
50.43
Price to sales (P/S)
6.22
EV/EBIT
45.44
EV/EBITDA
23.08
EV/Sales
7.26
Revenue
$55B
EBIT
$8.79B
EBITDA
$17.31B
Free cash flow
$17.78B
Per share
Balance sheet
Liquidity
EPS
$3
Free cash flow per share
$10.06
Book value per share
$3.84
Revenue per share
$31.11
TBVPS
$27.32
Total assets
$141.94B
Total liabilities
$135.12B
Debt
$70.63B
Equity
$6.78B
Working capital
-$8.1B
Debt to equity
10.42
Current ratio
0.81
Quick ratio
0.59
Net debt/EBITDA
3.32
Margins
Efficiency
Dividend
EBITDA margin
31.5%
Gross margin
62.8%
Net margin
9.7%
Operating margin
22.3%
Return on assets
3.8%
Return on equity
57.3%
Return on invested capital
14.3%
Return on capital employed
8.8%
Return on sales
16%
Dividend yield
3.17%
DPS
$6.13
Payout ratio
204.3%
ABBV stock price
How has the AbbVie stock price performed over time
Intraday
0.07%
1 week
-0.52%
1 month
-0.17%
1 year
25.75%
YTD
24.91%
QTD
12.86%
Financial performance
How have AbbVie's revenue and profit performed over time
Revenue
$55B
Gross profit
$34.52B
Operating income
$12.27B
Net income
$5.34B
Gross margin
62.8%
Net margin
9.7%
The company's net income fell by 39% YoY and by 11% QoQ
The net margin has declined by 37% year-on-year and by 12% since the previous quarter
The operating income has contracted by 29% YoY and by 4% from the previous quarter
The operating margin has declined by 28% year-on-year and by 5% since the previous quarter
Growth
What is AbbVie's growth rate over time
Valuation
What is AbbVie stock price valuation
P/E
64.53
P/B
50.43
P/S
6.22
EV/EBIT
45.44
EV/EBITDA
23.08
EV/Sales
7.26
ABBV's P/E is 108% above its 5-year quarterly average of 31.0 and 24% above its last 4 quarters average of 52.2
The EPS has contracted by 39% YoY and by 11% from the previous quarter
ABBV's price to book (P/B) is 156% higher than its 5-year quarterly average of 19.7 and 51% higher than its last 4 quarters average of 33.3
AbbVie's equity has decreased by 47% YoY and by 15% from the previous quarter
ABBV's P/S is 41% above its 5-year quarterly average of 4.4 and 17% above its last 4 quarters average of 5.3
Efficiency
How efficient is AbbVie business performance
AbbVie's return on assets has decreased by 40% YoY and by 12% QoQ
The ROS has contracted by 27% YoY and by 5% from the previous quarter
AbbVie's ROIC has decreased by 26% YoY and by 6% from the previous quarter
The ROE has grown by 3.6% from the previous quarter but it has contracted by 2.1% YoY
Dividends
What is ABBV's dividend history
DPS
$6.13
Dividend yield
3.17%
Payout ratio
204.3%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did AbbVie financials performed over time
AbbVie's total assets is 5% higher than its total liabilities
The quick ratio has contracted by 18% from the previous quarter and by 6% YoY
ABBV's current ratio is down by 14% since the previous quarter and by 9% year-on-year
The company's debt to equity has surged by 120% YoY and by 13% QoQ
AbbVie's equity has decreased by 47% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.